Compare Ascendis Pharma A/S (ASND) vs Tractor Supply Co (TSCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Tractor Supply Co — how do they compare? Ascendis Pharma A/S trades at $256.37 (market cap $16.67B), while Tractor Supply Co trades at $36.27 (market cap $18.39B). The key difference: Ascendis Pharma A/S and Tractor Supply Co are close in size by market cap, and Tractor Supply Co pays a 2.72% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TSCO | |
|---|---|---|
Market Cap | $16.67B | $18.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $62.65 |
52-Week Low | $189.74 | $29.14 |
Enterprise Value | $17.04B | $24.70B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
TSCO trades at $34.62, up 0.17% today, with a bullish technical signal from moving averages but bearish oscillators. The stock has missed earnings expectations for three consecutive quarters, with Q3 2026 results pending. Revenue has grown steadily from $14.2B in 2022 to $15.5B in 2025, though net income margin has declined. Recent news highlights cost pressures and a lowered 2026 outlook, alongside strategic initiatives like pet product expansion and dividend payments.
The outlook is mixed: a consensus price target of $36.29 suggests modest upside, but near-term headwinds from weak discretionary demand and higher costs pose risks. Long-term opportunities include digital growth and store investments, yet investor sentiment remains cautious amid earnings misses and guidance cuts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Tractor Supply Co
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,016 of its namesake banners in 49 states and 178 Petsense stores. Stores are typically located in towns outside of urban areas and in rural communities. In fiscal 2021, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).
Read more on TSCO →
